News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s
Other manufacturers may be spurred to follow suit and make similar price cuts, further intensifying competition in this booming segment of the weight-loss market
Pulses are our e-newsletters that look at recent trends and promising directions across life sciences
in many regions it is prescription-only and should be used under medical supervision to avoid masking other causes of neuropathy
There was a one-month increase of 18.6% in first-time AOM prescribing between December 2024 (when first-time AOMs accounted for 0.34% of all prescriptions) and January 2025 (when first-time AOMs accounted for 0.41% of all prescriptions)
The Tesamorelin Ipamorelin Growth Hormone Stack we offer is formulated specifically for research protocols that demand pharmacokinetic precision
